The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
|
4 min read
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
|
3 min read
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
|
3 min read
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
|
4 min read